Completed PHASE2 INTERVENTIONAL 4-arm NCT00526136

Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

Sponsor: Advanz Pharma

Interventions Placebo Vernakalant (oral)

Updated 8 times since 2017 Last updated: Dec 17, 2008 Started: Mar 31, 2007 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00526136, this PHASE2 trial focuses on Atrial Fibrillation and remains completed. Sponsored by Advanz Pharma, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Dec 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Advanz Pharma

Data source: Advanz Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ajka, Hungary , Amadora, Portugal , Amsterdam, Netherlands , Antwerp, Belgium , Arad, Romania , Auckland, New Zealand , Bad Krozingen, Germany , Bad Nauheim, Germany , Baja, Hungary and 109 more locations